Latest news with #PhaseII
NDTV
3 days ago
- Automotive
- NDTV
Hyundai Motor India Begins Engine Production At Talegaon Plant
Hyundai Motor India has announced commencement of operations at its recently acquired Talegaon manufacturing facility in Maharashtra. This facility will be used to manufacture powertrain and vehicles with the automaker initiating the process with the production of engines first. This is to be followed with the production of vehicles soon. In 2023, Hyundai Motor India finalized an agreement with General Motors to take over the latter's manufacturing plant located in Talegaon, found within the Phase II Expansion area of MIDC in Maval Tehsil, Pune district. This acquisition was part of Hyundai's long-term plan to boost its domestic production capabilities and reduce dependencies on imported components. It is important to note that General Motors operated their Talegaon facility until 2020, producing for specific export markets even after the American brand stopped operations in the Indian market in 2017. Since 2023, Hyundai has owned this facility and has been renovating it as part of its Rs 6,000 crore investment. Covering 300 acres, this Talegaon manufacturing site previously had an annual output capacity of 160,000 engines and 130,000 vehicles. Hyundai initiated engine production at this facility on June 16, 2025, which is anticipated to alleviate the production challenges prompted by the rising demand for Hyundai vehicles.
Hans India
5 days ago
- General
- Hans India
Rs 125 crore sanctioned for Metro Rail expansion works in Old City
Hyderabad: The Metro Rail expansion works in the Old City of Hyderabad is set to get momentum now, as the state government on Monday issued orders sanctioning Rs 125 crore. The Metro Rail works have begun in the Old City as part of the Hyderabad Metro Rail Phase II expansion. The initial phase involves road widening and construction of stations along a 7.5 kilometre stretch from MGBS to Chandrayangutta. This expansion aims to connect the Old City to the existing metro network. Around 1,100 properties were affected by the road widening and construction, and the acquisition process is underway with compensation being distributed to property owners. According to the HMR authorities, around 105 religious, historical, and sensitive structures exist in the corridor, and utmost care was being taken to ensure they remained unharmed.
Yahoo
5 days ago
- Business
- Yahoo
J&J reports results from antibody combo trial for MM patients
Johnson & Johnson (J&J) has reported new outcomes from the Phase II RedirecTT-1 trial of bispecific antibodies, Talvey (talquetamab-tgvs) and Tecvayli (teclistamab-cqyv) for relapsed/refractory multiple myeloma (r/r MM). The data showed a high overall response rate (ORR) with durability in those who have triple-class-exposed (TCE) RRMM with true extramedullary disease (EMD). In the trial, which enrolled 90 subjects, the investigational combo resulted in an ORR of 78.9%, with over half of the subjects achieving a complete response or better, representing a significant improvement over the average ORR of less than 40% for this patient group. Notably, responses were also found to be high among those previously treated with B-cell maturation antigen (BCMA) CAR-T or anti-FcRH5 bispecific antibodies. According to the company, subjects in the trial showed deep and durable responses, with 66.2% remaining in response at the data cutoff and a median follow-up of 13.4 months. At one year, 61% of subjects were progression-free and alive, and 74.5% were alive, with median overall survival not yet reached. The combo was found to be consistent with prior reports of them as single agents. Subjects had the option to switch to once-a-month dosing, which might have contributed to better tolerability. The reports of cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) were found to be mostly low grade. The study's findings were featured at the 2025 European Hematology Association Congress. EMD represents a severe form of MM, where myeloma cells form tumours in soft tissues and organs. Johnson & Johnson innovative medicine multiple myeloma disease area leader and vice-president Jordan Schecter said: 'Patients with extramedullary myeloma, especially those who have exhausted prior therapies, need more effective treatment options. 'Our first-in-class bispecific antibodies, Talvey and Tecvayli, have transformed treatment for relapsed or refractory multiple myeloma.' Recently, J&J reported that Tremfya decreased the symptoms and signs of active psoriatic arthritis (PsA) at 24 weeks in individuals against a placebo in the Phase IIIb APEX trial. "J&J reports results from antibody combo trial for MM patients" was originally created and published by Clinical Trials Arena, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
New Indian Express
13-06-2025
- New Indian Express
Biker killed as CMRL girders crash at Manapakkam in Chennai
CHENNAI: A biker was crushed to death after two I-girders, which were recently erected, collapsed on Thursday night at a Chennai Metro Rail construction site near the main gate of the L&T head office in Manapakkam. While the Chennai Metro Rail Limited (CMRL) and police officially confirmed the death of the biker, police sources said one more person could have gotten trapped under the girder. 'It is being ascertained whether the motorcycle had a pillion rider,' a CMRL statement said. The crash happened around 10.30pm along Corridor 5 of the Chennai Metro Phase II expansion project. According to CMRL officials, the girder, part of an elevated viaduct, came crashing down after one of its supporting frames slipped. Police fear one more person may be trapped under concrete girder In elevated metro construction sites, precast I-girders are usually lifted and placed between piers to form the base of the viaduct over which metro trains will run. Senior CMRL officials rushed to the site, and the statement from the agency said efforts to clear the mammoth concrete structure were under way on a 'war footing' in coordination with contractors.
Time of India
11-06-2025
- Business
- Time of India
Adani Power shares snap 5-day rally, slip over 1% amid profit-taking
Shares of Adani Power slipped as much as 1.2% on Wednesday to Rs 589 on the BSE, snapping a five-day rally that saw the stock surge nearly 12% since June 3. The decline appears to reflect profit-booking after a sharp upward move driven by a combination of technical strength and long-term growth triggers. The stock had rallied to an intraday high of Rs 610 on Tuesday, gaining 8.2% during the session and marking its fifth consecutive day of gains. Despite a mixed March-quarter performance—with net profit falling 4% year-on-year to Rs 2,637 crore and a sequential decline of 14%—investor sentiment remained upbeat, supported by long-term order wins and capacity expansion plans . Revenue for the quarter rose 6.5% YoY to Rs 14,237 crore, though it fell 4% compared to the December quarter. Total expenses during the period surged 9% YoY to Rs 11,274 crore. Order Wins and Capacity Expansion in Focus The recent rally was partially driven by Adani Power's announcement in May of a Rs 2 billion greenfield thermal power project . The company secured a Letter of Award to supply 1,500 MW of electricity to Uttar Pradesh Power Corporation Ltd under a long-term power purchase agreement. The power will be generated from a 2×800 MW ultra-supercritical plant, developed under the DBFOO (Design, Build, Finance, Own, and Operate) model. Brokerage InCred Equities, which initiated coverage in May with an 'Add' rating and a price target of Rs 649, described Adani Power as a 'pure play on the Indian thermal space.' It noted that the company generated Rs 200 billion in recurring EBITDA in FY25, backed by a stable revenue mix. InCred also highlighted the company's merchant power exposure via the Indian Energy Exchange (IEX), with realised prices ranging from Rs 5–6/kWh and peaking at Rs 10/kWh. Looking ahead, Adani Power plans to expand capacity from 17.55 GW to 30.67 GW by FY30, including brownfield additions such as Mahan Phase II (1.66 GW), Raipur Phase II (1.66 GW), and Korba Revival (1.32 GW). InCred noted that this expansion aligns with India's projected 5–6% annual power demand growth, which is expected to drive peak demand to 458 GW by FY32F. Technical Indicators Support the Uptrend Despite muted earnings, technical indicators remained supportive. The stock has been trading above all eight key simple moving averages—from the 5-day to the 200-day SMA. The Relative Strength Index (RSI) stood at 68.8, near the overbought threshold of 70, while the MACD reading of 6.9 stayed above both its center and signal lines, reinforcing bullish momentum until the latest dip. Valuation Concerns After Recent Spike While the stock has gained 15.4% over the past month and 8.5% in the past week, it remains down 23% over the past year, underperforming both the Nifty 50 and Nifty Energy indices. According to Trendlyne, analyst sentiment remains strong, with a consensus 'Strong Buy' rating on the stock. Also read | From bankruptcy to bull run: Can Reliance Infra & Reliance Power fuel Anil Ambani's comeback saga? ( Disclaimer : Recommendations, suggestions, views, and opinions given by the experts are their own. These do not represent the views of The Economic Times)
